Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
← catalyst calendarSponsored by Cellectis S.A. (industry) · CLLS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
29actual
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-06-19 | actual | When the study began enrolling |
| Primary completion | 2024-12-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2017-06-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory Acute Myeloid Leukemia
Intervention
- Biological: UCART123v1.2
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) [Safety and Tolerability]
measured 24 Months
Dose escalation and expansion part: Occurrence of DLTs
measured Up to Day 28 post last UCART123v1.2 infusion
Permalink · CLLS's whole pipeline · Catalyst calendar · Every registered study · What changed